Inactive Instrument

All News KetamineOne Capital Deutsche Boerse AG

Equities

MY00

CA4925531028

All News

Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference	23-06-19	BU
Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group	23-06-16	BU
Cardinal Group Companies LLC entered into an agreement to acquire KGK Science Inc. from Wellbeing Digital Sciences Inc. for $2 million.	23-06-15	CI
Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference	23-05-25	BU
Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response	23-05-03	BU
Wellbeing Digital Sciences Inc.'s Wholly Owned Subsidiary KGK Sciences Inc Begins Recruitment in First-Of-Its-Kind Health Canada Approved Psilocybin Trial	23-04-18	CI
Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial	23-04-18	BU
Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval	23-04-11	BU
Wellbeing Announces Cease Trade Order	23-04-06	BU
IIROC Trading Halt - MEDI	23-04-06	AQ
Wellbeing Provides Bi-Weekly Default Status Report	23-03-16	BU
Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference	23-03-16	BU
Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion	23-03-13	BU
Wellbeing Digital to Participate in The Global Biomedical Design Conference	23-03-09	BU
Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout	23-03-08	BU
Wellbeing Provides Bi-Weekly Default Status Report	23-03-02	BU
Wellbeing Digital to Participate in MarigoldLIVE: International Women’s Day Networking Event	23-03-01	BU
Wellbeing Provides Bi-Weekly Default Status Report	23-02-16	BU
Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.	23-02-15	BU
Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial	23-02-14	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News KetamineOne Capital Deutsche Boerse AG

Equities

MY00

CA4925531028

All News

Filters